
AZD6244 (Selumetinib)

产品编号: D50743

CAS: 606143-52-6

分子式: C₁₇H₁₅BrClFN₄O₃

纯度: ≥98%

InChi: InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)

InChi Key: CYOHGALHFOKKQC-UHFFFAOYSA-N

Smiles: CN1C=NC2C(F)=C(NC3C=CC(Br)=CC=3Cl)C(=CC1=2)C(=O)NOCCO

外观: 固体粉末

作用通路: Apoptosis

溶解性: DMSO up to 100 mM

保存条件: Store in dry, dark place for one year.

产品介绍: AZD6244 (Selumetinib, ARRY-142886) is an orally active, highly potent and selective non-ATP competitive MEK inhibitor, inhibiting MEK1 with an IC₅₀ of 14 nM. In vitro cell viability inhibition screening of a tumor cell line panel found that cell lines harboring BRAF or RAS mutations were more likely to be sensitive to AZD6244. Treatment of primary HCC cells with AZD6244 led to growth inhibition, caspase-3 and caspase-7 activation, poly(ADP)ribose polymerase cleavage, and inhibition of ERK1/2 and p90RSK phosphorylation. AZD6244 significantly inhibits phosphorylation of ERK1/2 in 2-1318, 5-1318, 26-1004 and 4-1318 xenografts and induces apoptosis in primary 2-1318 cells by activating the caspase pathway. Currently AZD6244 is undergoing Phase II/III clinical trials to treat solid tumors.